Microbio Co Ltd (4128) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Microbio Co Ltd (4128) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$51.95 Million ≈ $1.64 Million USD) by net assets (NT$10.40 Billion ≈ $327.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Microbio Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Microbio Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 4128 current and long-term liabilities for a breakdown of total debt and financial obligations.
Microbio Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Microbio Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
|
0.049x |
|
Companhia Brasileira de Distribuição
F:C1B2
|
-0.073x |
|
Vátryggingafélag Íslands hf
IC:SKAGI
|
0.083x |
|
E Split Corp Class A
TO:ENS
|
0.100x |
|
NACCO Industries Inc
NYSE:NC
|
0.027x |
|
Norwood Financial Corp
NASDAQ:NWFL
|
0.039x |
|
Rossari Biotech Limited
NSE:ROSSARI
|
0.024x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.023x |
Annual Cash Flow Conversion Efficiency for Microbio Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Microbio Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see 4128 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$11.87 Billion ≈ $373.94 Million |
NT$529.90 Million ≈ $16.69 Million |
0.045x | +871.28% |
| 2023-12-31 | NT$13.50 Billion ≈ $425.34 Million |
NT$-78.15 Million ≈ $-2.46 Million |
-0.006x | -157.28% |
| 2022-12-31 | NT$14.01 Billion ≈ $441.34 Million |
NT$141.57 Million ≈ $4.46 Million |
0.010x | +159.17% |
| 2021-12-31 | NT$13.84 Billion ≈ $436.15 Million |
NT$53.98 Million ≈ $1.70 Million |
0.004x | -54.37% |
| 2020-12-31 | NT$12.85 Billion ≈ $404.91 Million |
NT$109.82 Million ≈ $3.46 Million |
0.009x | +6.78% |
| 2019-12-31 | NT$9.04 Billion ≈ $284.89 Million |
NT$72.36 Million ≈ $2.28 Million |
0.008x | +388.65% |
| 2018-12-31 | NT$9.68 Billion ≈ $304.91 Million |
NT$15.85 Million ≈ $499.33K |
0.002x | +238.29% |
| 2017-12-31 | NT$8.30 Billion ≈ $261.53 Million |
NT$-9.83 Million ≈ $-309.70K |
-0.001x | +94.47% |
| 2016-12-31 | NT$8.41 Billion ≈ $265.04 Million |
NT$-180.25 Million ≈ $-5.68 Million |
-0.021x | -18.36% |
| 2015-12-31 | NT$8.94 Billion ≈ $281.77 Million |
NT$-161.90 Million ≈ $-5.10 Million |
-0.018x | +1.39% |
| 2014-12-31 | NT$9.10 Billion ≈ $286.68 Million |
NT$-167.04 Million ≈ $-5.26 Million |
-0.018x | +9.53% |
| 2013-12-31 | NT$8.70 Billion ≈ $274.25 Million |
NT$-176.63 Million ≈ $-5.56 Million |
-0.020x | +3.13% |
| 2012-12-31 | NT$6.32 Billion ≈ $199.08 Million |
NT$-132.36 Million ≈ $-4.17 Million |
-0.021x | +51.99% |
| 2011-12-31 | NT$6.23 Billion ≈ $196.39 Million |
NT$-271.95 Million ≈ $-8.57 Million |
-0.044x | -142.24% |
| 2010-12-31 | NT$5.04 Billion ≈ $158.75 Million |
NT$520.41 Million ≈ $16.40 Million |
0.103x | +211.97% |
| 2009-12-31 | NT$5.26 Billion ≈ $165.69 Million |
NT$-485.10 Million ≈ $-15.28 Million |
-0.092x | -15.56% |
| 2008-12-31 | NT$1.79 Billion ≈ $56.53 Million |
NT$-143.21 Million ≈ $-4.51 Million |
-0.080x | -8.41% |
| 2007-12-31 | NT$1.29 Billion ≈ $40.78 Million |
NT$-95.30 Million ≈ $-3.00 Million |
-0.074x | -1038.56% |
| 2006-12-31 | NT$559.40 Million ≈ $17.62 Million |
NT$4.39 Million ≈ $138.25K |
0.008x | -- |
About Microbio Co Ltd
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; pr… Read more